Overexpression of transforming growth factor-beta1 in scirrhous carcinoma of the stomach correlates with decreased survival

Oncology. 1998 Nov-Dec;55(6):582-7. doi: 10.1159/000011916.

Abstract

A retrospective study of 50 patients with scirrhous carcinoma of the stomach who had undergone surgery was performed to elucidate whether immunohistochemical overexpression of transforming growth factor-beta1 (TGF-beta1) could predict the patients' survival. To evaluate the proliferative activity of the tumor, the proliferating cell nuclear antigen (PCNA) index was used. Expression of TGF-beta1 was low in 27 patients and high in 23. Clinicopathological characteristics were not significantly different between the two groups with high and low TGF-beta1 expression. Tumors with higher TGF-beta1 expression had higher PCNA indices (p = 0.0467, unpaired Student's t test). The 5-year survival rate was 40.4% for the low TGF-beta1 group and 28.7% for the high TGF-beta1 group (p = 0.0388, log rank test). By multivariate analysis, pT, residual tumor, and TGF-beta1 were the independent prognostic factors. These results suggest that immunohistochemical expression of TGF-beta1 is one of the useful predictors for estimating the patients' survival in scirrhous carcinoma of the stomach particularly of the T3 and T4 stages.

MeSH terms

  • Adenocarcinoma, Scirrhous / genetics
  • Adenocarcinoma, Scirrhous / metabolism*
  • Adenocarcinoma, Scirrhous / pathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Staging
  • Prognosis
  • Proliferating Cell Nuclear Antigen / metabolism
  • Retrospective Studies
  • Stomach Neoplasms / metabolism*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery
  • Transforming Growth Factor beta / biosynthesis*

Substances

  • Proliferating Cell Nuclear Antigen
  • Transforming Growth Factor beta